About Nivalis
Nivalis is a Healthcare company based in Boulder (United States) founded in 2007, and was acquired by Alpine Immune Sciences in April 2017. Small molecule therapeutics for cystic fibrosis are developed. Nivalis has raised $50 million across 5 funding rounds from investors including Alpine Immune Sciences, RA Capital and Jennison Associates. Its focus areas include Life Sciences, Rare Diseases, Drugs and Metabolic Disorders. Its competitors include Alnylam, Ultragenyx and Gemini Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Nivalis was founded in 2007 in Boulder, United States, within the biotechnology sector. Small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) are developed by the company for cystic fibrosis treatment. Focus is placed on patients homozygous for the F508del mutation in the CFTR gene. The lead candidate has advanced to phase II clinical trials, addressing clinical needs in this area.
- Headquarters Boulder, United States
- Stage Acquired
- SectorsHealthcare
- Website nivalis.com
- Social LinkedIn X
- Acquired by Alpine Immune Sciences (Apr 2017)
- Total Equity Funding$50M (USD)
in 5 rounds
- Latest Funding Round$30M (USD), Series C
Nov 2014
- InvestorsAlpine Immune Sciences
& 8 more
- Acquired byAlpine Immune Sciences
(Apr 2017)
Funding Insights of Nivalis
Nivalis has successfully raised a total of $50M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $30 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $50M
- Total Rounds 5
- Last Round Series C — $30M
- Investors Count 8
All 5 funding rounds of Nivalis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2014 | $30M | Series C | – | – | |
| Nov 2014 | $30M | Debt – Conventional | – | – | |
| Jul 2010 | $10M | Series B | – | – | |
| May 2010 | $10M | Series B | – | – | |
| Oct 2008 | Series A | – | – | – |
9 investors in total: 9 institutional.
Investors in Nivalis
Nivalis has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Alpine Immune Sciences, RA Capital and Jennison Associates.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Venture and private equity investments are managed with global diversification. | tigerglobal.com | New York, United States | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Offers asset management and advisory for equities and fixed income portfolios. | 1969 | jennison.com | New York, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States | ||
Provides asset management and investment advisory services. | 1994 | deerfieldcapital.com | Springfield, United States | |
| bridger-capital.com | ||||
Developer of immunotherapies to treat cancer and autoimmune disorders | 2015 | alpineimmunesciences.com | Seattle, United States |
Investor details for Nivalis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Nivalis
4 dated milestones of Nivalis across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Nivalis is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $30.0M.
- Exit Acquired by Alpine Immune Sciences.
Competitors of Nivalis
Nivalis has 3 listed competitors in our database, 3 of them funded. They include Alnylam, Ultragenyx and Gemini Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| geminitherapeutics.com | 2015 | Cambridge, United States | $44.5M | 45 | Developer of precision therapeutics for dry AMD and rare genetic diseases |
Detailed competitors of Nivalis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Rare Diseases
3 companies that operate in the same segment as Nivalis (Rare Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nivalis
Complete news archive for Nivalis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nivalis
Nivalis was founded in 2007 and raised its 1st funding round 1 year after it was founded.
Nivalis is headquartered in Boulder, United States. It is registered at Boulder, Colorado, United States.
Nivalis is a funded company, having raised a total of $50M across 5 funding rounds to date.
Nivalis was founded in 2007 in Boulder, United States, within the biotechnology sector. Small molecule inhibitors of S-nitrosoglutathione reductase (GSNOR) are developed by the company for cystic fibrosis treatment. Focus is placed on patients homozygous for the F508del mutation in the CFTR gene. The lead candidate has advanced to phase II clinical trials, addressing clinical needs in this area.
Nivalis's top competitors include Alnylam, Ultragenyx and Gemini Therapeutics.
Nivalis has 9 investors. Key investors include Alpine Immune Sciences, RA Capital, Jennison Associates, Rock Springs Capital, and Deerfield.
Yes. Nivalis was acquired by Alpine Immune Sciences in April 2017.